Immuno-Oncology 360° Community News’ Post

Sepsis and newly diagnosed Multiple Myeloma (MM): a great risk, associated with poor outcomes. A retrospective study by Desantis V., et al. observed the relationship between clinical conditions, the disease stage, the type of germ involved, and the PFS in this specific cohort of patients. Full: https://buff.ly/4eNblhv #MM #MultipleMyeloma #Sepsis # PFS #NewlyDiagnosed

Subclinical disease can wreck havoc on your profitability. Measuring and responding to subclinical challenges is key to getting poultry producers ready for the next stage of growth.

Necrotic enteritis (NE) is a devastating disease in the broiler industry, causing economic losses that extend far beyond high mortality rates. In addition, the sudden death caused by the disease often prevents treatment.   Seeing the need for an alternative to the labor- and time-intensive conventional diagnostic testing for NE, Ancera recently developed a non-invasive method to monitor Clostridium perfringens levels before clinical symptoms are observed, which could help effectively prevent and treat the disease.   “Ancera’s non-invasive PIPER assay delivers preemptive disease identification and efficient monitoring at scale,” writes Margaret Kiss, PhD, Ancera. Read more about this at https://lnkd.in/e4T4ST6B #poultryproduction #necroticenteritis

There are more than 100 known autoimmune diseases, including rare autoantibody-driven conditions such as generalized myasthenia gravis, warm autoimmune hemolytic anemia, chronic inflammatory demyelinating polyneuropathy and idiopathic inflammatory myopathies. Patient advocates like Elisa are key partners to gaining insights that help increase understanding of these conditions. For this #AutoimmuneAwarenessMonth, our unwavering research, and ongoing efforts to increase treatment options for people living with rare autoantibody diseases remain at forefront, building on our commitment to deliver safer, more effective approaches: https://bit.ly/3IyA62d #JNJImmunology

Did you know? MASH, or metabolic dysfunction-associated steatohepatitis, is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not managed properly. It is often described as a ‘silent disease’ due to the lack of specific symptoms in the early stages of the disease, which often contributes to a delay in diagnosis. 13 June is Global #FattyLiverDay 🌎 Learn more about living with the condition and the impact of a late diagnosis from Tania. Watch Tania’s story here: https://lnkd.in/dAw55qZV At Novo Nordisk, we are committed to continuing our research with the ambition of developing innovations that can help address the underlying cause of this disease. We hope to double diagnostic rates for people living with moderate to advanced MASH by 2027 💙

INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (September 9): Is the achievement of sputum culture conversion in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) and cavitary lesions associated with the prognosis? Read the full original research in the September issue to learn more: https://hubs.ly/Q02NR5wG0 #MedEd #JournalCHEST

New publication 📝 Phase III BLISS-BELIEVE trial, published in Annals of the Rheumatic Diseases, evaluates belimumab–rituximab sequential therapy in patients with SLE after corticosteroid and immunosuppressant withdrawal. See: https://loom.ly/593jzXg #RheumTwitter #lupus #MedNews #MedEd

📣 New Publication to inform our guideline on the management of critical bleeding in patients with immune thrombocytopenia - 👉 Common treatments were corticosteroids, IVIG, platelet transfusions, TPO-RAs, and urgent splenectomy either alone or in combination. 👉 Mortality was 30.6% for adults and 19.7% for children. Link: https://lnkd.in/ezVJgntR

MannKind announced today that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases – including idiopathic pulmonary fibrosis (IPF). According to @PulmonaryFibrosisFoundation, there are more than 250,000 Americans living with pulmonary fibrosis (PF) today with 50,000 new cases diagnosed each year. Sadly, as many as 40,000 Americans die from IPF each year. MannKind now has two studies in motion that will explore the potential treatment options for patients living with serious lung diseases. https://bit.ly/3Wio8lg #MNKD #Pulmonary #Lungs

Thank you to Greg Deener for sharing valuable insights on current and future opportunities in advancing #cell_therapy for #autoimmune diseases. • Over 50 companies are now developing CAR therapies for lupus and other autoimmune conditions. • Approximately 50 patients have been reported in published, publicly available data so far. • This number is expected to grow significantly over the next two years, highlighting the potential need for tailored approaches across different diseases and subpopulations.